Name: Apimeds Pharmaceuticals US, Inc. (APUS) Cash Flow Statement
Creator: FinSpry

Apimeds Pharmaceuticals US Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Apimeds Pharmaceuticals US, Inc. (APUS) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Operating Activities
Net Income	-1.39	-0.78	-0.67	-1.03
Stock Based Compensation	0.00	0.07	0.19	0.19
Change in Working Capital	0.54	0.04	0.00	0.00
Change in Accounts Payable	0.00	0.05	0.00	0.00
Change in Other Working Capital	0.54	-0.01	0.03	0.00
Other Operating Activities	0.12	0.04	0.03	0.01
Net Cash from Operating Activities	-0.73	-0.63	-0.45	-0.82
Investing Activities
Net Cash from Investing Activities	0.00	0.00	0.00	0.00
Financing Activities
Debt Repayment	0.25	-0.03	0.00	0.00
Common Stock Issued	0.00	1.06	0.00	0.00
Other Financing Activities	0.08	-0.02	0.02	0.00
Net Cash from Financing Activities	0.33	1.03	0.28	0.40
Summary
Net Change in Cash	-0.41	0.40	-0.17	-0.42
Cash at Beginning of Period	0.41	0.01	0.17	0.59
Cash at End of Period	0.00	0.41	0.01	0.17
Free Cash Flow	-0.73	-0.63	-0.45	-0.82